Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given Neutral Rating at Wedbush

Wedbush reaffirmed their neutral rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note published on Friday,Benzinga reports. They currently have a $4.00 price target on the stock.

A number of other analysts have also weighed in on the company. Wells Fargo & Company dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. UBS Group cut their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $1.81 on Friday. The stock has a market capitalization of $128.99 million, a P/E ratio of -0.73 and a beta of 1.75. Zentalis Pharmaceuticals has a one year low of $1.61 and a one year high of $16.27. The firm’s 50 day simple moving average is $2.04 and its two-hundred day simple moving average is $2.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. The company had revenue of $26.90 million for the quarter. As a group, equities analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Ingmar Bruns acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The shares were bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This trade represents a 120.27 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jan Skvarka bought 60,000 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was purchased at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the acquisition, the director now directly owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. The trade was a 67.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Corton Capital Inc. purchased a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter valued at about $32,000. Captrust Financial Advisors purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $33,000. Erste Asset Management GmbH bought a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Paloma Partners Management Co bought a new stake in shares of Zentalis Pharmaceuticals in the third quarter worth $37,000. Finally, Prudential Financial Inc. purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at $39,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.